B. J. Coventry, S. C. Weeks, S. E. Heckford, P. J. Sykes, J. Bradley and J. M. Skinner, “Lack of IL-2 Cytokine Expression despite Il-2 Messenger RNA Transcription in Tumor Infiltrating Lymphocytes in Primary Human Breast Carcinoma: Selective Expression of Early Activation Markers,” Journal of Immunology, Vol.156, No.9, 1996, pp 3486-92.

has been cited by the following article:

• TITLE: Immuno-Chemotherapy Using Repeated Vaccine Treatment Can Produce Successful Clinical Responses in Advanced Metastatic Melanoma

  AUTHORS: Brendon Coventry, Peter Hersey, Anne-Marie Halligan, Antonio Michele

  KEYWORDS: Vaccine Therapy, Combined Immuno-Chemotherapy, Repetitive Dosing, Advanced Melanoma, Clinical Responses, Prolonged Survival

  JOURNAL NAME: Journal of Cancer Therapy, Vol.1 No.4, December 31, 2010

  ABSTRACT: Advanced Stage IV and IIIc melanoma has a dismal survival, with or without, standard chemotherapy. New therapies are required to improve survival and reduce morbidity. Repeated vaccine dosing does not appear to have been explored, so Vaccinia Melanoma Cell Lysate (VMCL) vaccine repetitive therapy was tested, either alone, or combined with chemotherapy. 37 patients (31 Stage IV [M1a(6), b(7), c(18)] and 6 Stage IIIc) were studied using intra-dermal VMCL vaccine therapy. If disease progressed, vaccine was continued with standard chemotherapy (DTIC and/or Fotemustine). Overall survival was assessed and clinical responses were also recorded. From vaccine commencement, median overall follow-up was 10 months. Survivals ranged from 4 to 73 months. Median (mean) overall survival was 10 (23.5) months; overall survival at 1, 2 and 3 years was 40.5%, 21.6% and 10.8% respectively. CR and PR occurred in 18.9% (7) and 18.9% (7) of patients; these were durable for up to 6.1 years in 4 patients. Stable disease was noted in a further 17 patients (45.9%). In 6 patients (16.2%) no response to therapy was apparent. Repeated vaccinations with or without chemotherapy produced strong, durable clinical responses with overall survival > 23 months occurring in nearly 25% of advanced melanoma patients. The overall disease control rate (CR, PR and SD) was 83.7%, including CR in very advanced cases. These results, in a largely unselected population of advanced metastatic melanoma patients, compare very favourably with other regimens, and notably were associated with minimal, if any, toxicity. Further analysis of this approach appears warranted.